Clinical research, Pharmacology, Clinical trial, Pharmaceutical industry, Informed consent, Clinical data acquisition
FDA clears Roche’s bispecific Eylea contender, but can it compete with the Regeneron blockbuster?
The FDA finally approved Roche-Genentech’s Eylea rival late Friday, although precisely how much the long-acting antibody can cut into Regeneron’s blockbuster sales remains unclear. ...
FDA clears Roche’s bispecific Eylea contender, but can it compete with the Regeneron blockbuster?
The FDA finally approved Roche-Genentech’s Eylea rival late Friday, although precisely how much the long-acting antibody can cut into Regeneron’s blockbuster sales remains unclear. ...
We are sorry, we could not find the related article
If you are curious about Biotech and Career and Jobs
Please click on:
Subscribe to Biotech - Career and Jobs
UPDATED: Waking up from some big blockbuster dreams, Pfizer scraps a $250M drug deal as data sour, safety fears rise
A little over 2 years after Pfizer paid Ionis $250 million cash to in-license rights to vupanorsen (AKCEA-ANGPTL3-LRx) - immediately vaulting the drug onto its list of top prospects — the ...
2022 Pipeline Report: Capitalizing on Opportunity
Our annual report takes a look at pharma’s current investment in drug development, which this year demonstrates a focus on five important therapeutic areas of interest—Alzheimer’s disease, ...
Clinical Catch-Up: October 4-8
Another busy week for clinical trial news. Here’s a look.
4 Life Science Trends To Pay Attention To in 2021
With COVID-19 having dominated the headlines in 2020, the coronavirus pandemic will inevitably continue to be the biggest story in 2021, but hopefully for more positive reasons. This year ...
#PHARMA : on LEEM un peu, beaucoup, passionnément…pas du tout #hcsmeufr
Cette semaine est une semaine importante dans le microcosme de l’industrie pharmaceutique. Mardi 11 septembre sera élu(e) le nouveau (ou la nouvelle) président(e) du LEEM, l’organisation […]
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks. Although there were promising updates from...
Covid-19 is forcing pharma to rethink clinical trials
Drug trials have become a casualty of Covid-19, but the pandemic is also prompting change
Seven Biopharma Trends to Watch in 2021
It’s not all COVID-19! Check out gene editing, gene and cell therapy, and other areas.
ACTIV coming into focus, starting COVID-19 therapy trials in June
A consortium that is pooling the resources of the U.S.
Novartis CEO Who Wanted To Bring Tech Into Pharma Now Explains Why It's So Hard
We need to bring our best technology – biological and digital – and our most creative people together to work on this monumental challenge. One clear take-away from the Narasimhan ...
Digital therapeutics get first FDA clearance, Novartis focuses on digital after announcing job cuts and other Q4 pharma news
Also: The pharma industry continues to use digital technologies for R&D and diabetes management.
GlaxoSmithKline makes $300M investment in 23andMe, forms 50-50 R&D pact
GlaxoSmithKline has made a $300 million equity investment in 23andMe as part of a deal that pulls it close to the consumer genetics pioneer. The partners are contributing preclinical ...
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
Grail, a company developing blood tests intended to detect cancer well before symptoms show, is taking its pitch to a broader swath of investors. The
Transforming Clinical Trials with Real-World Evidence
Once a visionary ambition, synthetic control arms are poised to take off. Now is the time for pharma companies to identify opportunities and gain experience.